Prognostic factors and outcomes in anaplastic gliomas: An institutional experience
| Autor: | Syed Fayaz Ahmed, Monica Malik, Deepthi Valiyaveettil, Deepa Joseph, Syed Akram Kothwal |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Adjuvant chemotherapy medicine.medical_treatment Anaplastic gliomas temozolomide 01 natural sciences survival 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine medicine In patient chemoradiation Survival analysis Temozolomide 010405 organic chemistry business.industry ORIGINAL ARTICLE: Brain Tumors Astrocytoma medicine.disease 0104 chemical sciences Time to recurrence Oligodendroglioma business Adjuvant medicine.drug |
| Zdroj: | South Asian Journal of Cancer |
| ISSN: | 2278-4306 2278-330X |
| Popis: | Background: There is lack of clear evidence and treatment guidelines for anaplastic gliomas (AGs) with very few studies focusing exclusively on these patients. The aim of the study was to analyze the clinical profile and survival in these patients. Materials and Methods: Patients of AGs treated with radiation and concurrent ± adjuvant chemotherapy from January 2010 to December 2015 were analyzed. Statistical analysis was done using SPSS version 20 software. Results: A total of 100 patients were included in the study. The median age was 35 years (range 6–68 years). Eighty-four patients had follow-up details and were included for survival analysis. The 5-year overall survival (OS) was 58%. Age, presentation with seizures, and focal neurological deficit were not found to significantly influence survival. The 5-year survival for oligodendroglioma and astrocytoma was 69% and 52%, respectively. Patients with Karnofsky Performance Score (KPS) of ≥70 had a significantly better 5-year OS (65%) as compared to those with KPS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|